Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences

By afschroeder • June 19, 2026

Bruyat D, Girard N, Heudel P, Penel N, Le Deley MC, Diallo I, Boher JM, Zemmour C, Chanez B, Madroszyk A, Gravis G, Billon E, Lisberg A, Collineau B, Beaufils M, Gonçalves A, Tejeda M, Chrétien AS, Rochigneux P. Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences. Cancer Commun (Lond). 2026 Jun 17;46:0035. doi: 10.34133/cancomm.0035. PMID: 42318065; PMCID: PMC13273061.

Tags: Hematology/Oncology, Publications

Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology

Misic A, Ghanem G, Sadeghi S, Carroll M. Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology. Thromb J.[...]

Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia

Zuckerman JE, Larson S, Abdelnour L. Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. Kidney Med. 2026 May 12;8(7):101402. doi:[...]

Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer

Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):1-16.[...]